[{"address1": "26 Technology Drive", "city": "Irvine", "state": "CA", "zip": "92618", "country": "United States", "phone": "949 396 6322", "fax": "949 396 6321", "website": "https://www.axonics.com", "industry": "Medical Devices", "industryKey": "medical-devices", "industryDisp": "Medical Devices", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.", "fullTimeEmployees": 797, "companyOfficers": [{"maxAge": 1, "name": "Mr. Raymond W. Cohen", "age": 64, "title": "CEO & Director", "yearBorn": 1959, "fiscalYear": 2023, "totalPay": 1748200, "exercisedValue": 0, "unexercisedValue": 19990702}, {"maxAge": 1, "name": "Ms. Kari  Keese", "age": 38, "title": "Chief Financial Officer", "yearBorn": 1985, "fiscalYear": 2023, "totalPay": 1641620, "exercisedValue": 46744, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Rinda K. Sama", "age": 44, "title": "Chief Operating Officer", "yearBorn": 1979, "fiscalYear": 2023, "totalPay": 888200, "exercisedValue": 0, "unexercisedValue": 1273486}, {"maxAge": 1, "name": "Dr. John  Woock Ph.D.", "age": 40, "title": "Executive VP, Chief Marketing & Strategy Officer", "yearBorn": 1983, "fiscalYear": 2023, "totalPay": 888200, "exercisedValue": 1506483, "unexercisedValue": 912283}, {"maxAge": 1, "name": "Mr. Alfred J. Ford Jr.", "age": 52, "title": "Chief Commercial Officer", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 909520, "exercisedValue": 1904597, "unexercisedValue": 169489}, {"maxAge": 1, "name": "Mr. Guangqiang  Jiang Ph.D.", "age": 49, "title": "Chief Technology Officer", "yearBorn": 1974, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Neil  Bhalodkar", "title": "Vice President of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Aaron  Pettit", "title": "General Counsel & Chief Compliance Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael V. Williamson Esq., J.D.", "age": 51, "title": "Senior VP, General & IP Counsel", "yearBorn": 1972, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Karen L. Noblett M.A.S., M.D.", "age": 60, "title": "Chief Medical Officer", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 651400, "exercisedValue": 897471, "unexercisedValue": 626228}], "auditRisk": 10, "boardRisk": 3, "compensationRisk": 3, "shareHolderRightsRisk": 4, "overallRisk": 5, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 69.1, "open": 69.19, "dayLow": 68.7, "dayHigh": 69.19, "regularMarketPreviousClose": 69.1, "regularMarketOpen": 69.19, "regularMarketDayLow": 68.7, "regularMarketDayHigh": 69.19, "beta": 0.822, "forwardPE": 80.04651, "volume": 558927, "regularMarketVolume": 558927, "averageVolume": 332845, "averageVolume10days": 264940, "averageDailyVolume10Day": 264940, "bid": 49.75, "ask": 88.69, "bidSize": 200, "askSize": 200, "marketCap": 3518969856, "fiftyTwoWeekLow": 48.3, "fiftyTwoWeekHigh": 69.68, "priceToSalesTrailing12Months": 8.607859, "fiftyDayAverage": 68.3094, "twoHundredDayAverage": 66.29965, "currency": "USD", "enterpriseValue": 3221299968, "profitMargins": -0.00419, "floatShares": 50453527, "sharesOutstanding": 51118100, "sharesShort": 3288608, "sharesShortPriorMonth": 3240023, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.0643, "heldPercentInsiders": 0.01271, "heldPercentInstitutions": 0.86011004, "shortRatio": 9.23, "shortPercentOfFloat": 0.0726, "impliedSharesOutstanding": 51118100, "bookValue": 12.61, "priceToBook": 5.4591594, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -1711000, "trailingEps": -0.02, "forwardEps": 0.86, "pegRatio": 3.74, "enterpriseToRevenue": 7.88, "enterpriseToEbitda": 434.196, "52WeekChange": 0.22561193, "SandP52WeekChange": 0.24014747, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "AXNX", "underlyingSymbol": "AXNX", "shortName": "Axonics, Inc.", "longName": "Axonics, Inc.", "firstTradeDateEpochUtc": 1540992600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "c5b6415e-1751-345c-b606-e09d4a4f7a7f", "messageBoardId": "finmb_260926796", "gmtOffSetMilliseconds": -14400000, "currentPrice": 68.84, "recommendationMean": 2.9, "recommendationKey": "hold", "totalCash": 343411008, "totalCashPerShare": 6.718, "ebitda": 7419000, "totalDebt": 32453000, "quickRatio": 7.007, "currentRatio": 8.956, "totalRevenue": 408808992, "debtToEquity": 5.045, "revenuePerShare": 8.152, "returnOnAssets": -0.00457, "returnOnEquity": -0.00275, "freeCashflow": 24389750, "operatingCashflow": 25716000, "revenueGrowth": 0.233, "grossMargins": 0.75894, "ebitdaMargins": 0.01815, "operatingMargins": 0.05528, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]